Valuation: BioNTech SE

Market Cap 20.22B 23.13B 18.66B 17.2B 32.41B 2,228B 33.13B 223B 87.7B 1,091B 86.88B 84.97B 3,756B P/E 2026 *
-18.2x
P/E 2027 * -17.5x
Enterprise Value 9.36B 10.71B 8.64B 7.96B 15.01B 1,032B 15.34B 103B 40.61B 505B 40.23B 39.35B 1,739B EV / Sales 2026 *
4.32x
EV / Sales 2027 * 4.9x
Free-Float
96.06%
Yield 2026 *
-
Yield 2027 * -
1 day+0.31%
Current month-9.76%
Current year-9.76%
3 years 78.65
Extreme 78.65
115.95
5 years 78.65
Extreme 78.65
396.5
10 years 11.5
Extreme 11.5
396.5
Manager TitleAgeSince
Chief Tech/Sci/R&D Officer 59 31/12/2017
Chief Executive Officer 60 01/06/2008
Director of Finance/CFO - 30/06/2025
Director TitleAgeSince
Chairman 55 01/06/2008
Director/Board Member 69 01/06/2008
Director/Board Member 65 31/12/2017
Change 5-day change 1-year change 3-year change Capi.($)
+0.31%+0.06% - - 23.13B
+0.24%-1.54%+52.85%+71.85% 53.83B
-7.17%-4.39%+42.72%+73.32% 52.1B
+0.80%-6.31%+5.62%+417.78% 23.48B
-5.95%-2.58%+29.53%-9.47% 19.36B
-1.14%+0.03%+31.67%-30.65% 17.56B
-5.16%-7.00%+168.44%+314.96% 15.2B
-6.91%-5.83%+25.17%+644.30% 14.83B
+0.43%-1.03%+25.75%+189.74% 14.06B
+1.46%+3.13%+65.65%+152.36% 12.76B
Average -2.31%-2.28%+49.71%+202.69% 24.8B
Weighted average by Cap. -2.54%-2.28%+46.89%+160.09%

Financials

2026 *2027 *
Net sales 2.17B 2.48B 2B 1.84B 3.48B 239B 3.55B 23.91B 9.4B 117B 9.32B 9.11B 403B 2.23B 2.55B 2.06B 1.9B 3.58B 246B 3.66B 24.6B 9.68B 120B 9.59B 9.38B 414B
Net income -1.04B -1.19B -962M -886M -1.67B -115B -1.71B -11.49B -4.52B -56.25B -4.48B -4.38B -194B -1.16B -1.33B -1.07B -991M -1.87B -128B -1.91B -12.85B -5.05B -62.86B -5B -4.9B -216B
Net Debt -10.85B -12.42B -10.02B -9.23B -17.4B -1,196B -17.79B -120B -47.09B -586B -46.65B -45.62B -2,017B -9.29B -10.63B -8.57B -7.9B -14.89B -1,023B -15.22B -102B -40.28B -501B -39.9B -39.03B -1,725B
Logo BioNTech SE
BioNTech SE is a Germany-based clinical-stage biotechnology company. The Company focuses on patient-specific immunotherapies for the treatment of cancer and other serious diseases. The Company is providing technologies including mRNA-based therapies, cell therapies, small molecules and antibodies, which can be utilized for specific purposes or can be even combined with each other in a synergistic manner. It also develops a broad product pipeline using different scientific approaches and technology platforms, including individualized mRNA-based product candidates, chimeric antigen receptor T-cells, checkpoint immunomodulators, targeted cancer antibodies and small molecules. In addition, the Company offers diagnostic products and drug discovery services for other therapeutic areas, including infectious diseases, allergies and autoimmune disorders.
Employees
7,807
Date Price Change Volume
17/07/26 €80.10 +0.31% 2,365
16/07/26 €79.85 -0.25% 2,031
15/07/26 €80.05 +1.20% 1,007
14/07/26 €79.10 -0.06% 2,008
13/07/26 €79.15 -1.12% 2,149
Trader
Investor
-
Global
-
Quality
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
20
Last Close Price
79.94EUR
Average target price
106.79EUR
Spread / Average Target
+33.58%

Quarterly revenue - Rate of surprise